

Special Issue

HPV Vaccines and New Vaccination Schedules Implementation

Message from the Guest Editors

Human papillomavirus (HPV) vaccination programs are a primary prevention strategy for cervical cancer. They have made significant progress in preventing HPV-related diseases. Countries that have implemented these vaccination efforts have observed substantial reductions in HPV-related conditions, including decreases in high-grade cervical neoplasia and genital warts. However, global coverage remains imbalanced, with notable disparities between high-income and low-income countries. While effective programs exist, they remain suboptimal, thus the World Health Organization's strategy to eradicate cervical cancer faces an uncertain future. This Special Issue aims to provide insights into HPV vaccines and the burden of HPV-related diseases, including updates on HPV vaccine efficacy, HPV-related disease prevention, the status of HPV vaccination coverage, and estimates of the time required to meet vaccination targets in various countries. It will also examine barriers to HPV vaccination and address other issues surrounding the HPV vaccine. We welcome original research articles and reviews broadly covering these topics.

Guest Editors

Dr. Kirvis Torres-Poveda

Dr. Aurelio Cruz-Valdez

Dr. Vicente Madrid-Marina

Deadline for manuscript submissions

31 March 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/235259

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).